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1 Introduction
Problems in the newborn period can sometimes be
predicted by biochemical measurements in late
pregnancy but there is, as yet, no definitive pre-
natal indicator of poor fetal growth. Although
modern intensive care has improved the prognosis
for light weight infants, management still presents
problems especially when such births are unex-
pected.
At present, measurement of maternal serum α
fetoprotein (MSAFP) between 16 and 20 weeks
gestation is done primarily as a screening pro-
cedure for fetal neural tube defects (NTD). How-
ever, initial studies on the outcomes of pregnancies
where high MSAFP values were found in the
absence of fetal NTD suggested that these preg-
nancies were associated with low birth weight
babies [1, 7]. Since there is no evidence that
MSAFP measurement at any time other than in
the second trimester might predict low birth
weight infants more efficiently [2, 8], it would
be convenient if the routine MSAFP test were
clinically useful in this respect. SMITH [5] has sug-
gested that high MSAFP predicts prematurity
whereas PURDIE et al. [4] concluded that growth
retardation rather than prematurity was indicated.
We have examined MSAFP levels in pregnancies
resulting in low birth weight infants to assess their
relationship in our population. Women with pre-
mature delivery and those with light for gesta-
tional age infants were analysed separately to find
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whether raised MSAFP was associated with one or
both of these groups. Pregnancies ending in spon-
taneous abortion or stillbirth were also studied.
2 Patients and methods
Three hundred and eighty-nine pregnancies screened
for NTD in the period January 1980 to December
1981 and resulting in a liveborn singleton weighing
2.5 kg or less were included. The variables recorded
for each patient were birth weight, sex and gesta-
tion at birth, and MSAFP value expressed as a
multiple of the median (MOM) value according to
gestation for uncomplicated pregnancies with
normal outcome at term. Pregnancies which were
screened over the same period and ended in spon-
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taneous abortion or stillbirth were analysed sepa-
rately. The MSAFP value was described as raised if
it equalled or was greater than two multiples of
the median value (> 2 MOM) for normal outcome
in singleton pregnancies, otherwise it was classified
as normal. However, for pregnancies screened in
the Grampian Region of Scotland centered in
Aberdeen, a MSAFP value of 2 MOM is at the 95 %
centile of the normal range so that 5 % of normal
outcome pregnancies will have MSAFP at or above
this level. Using this information, a statistical com-
parison was made with the proportion of raised
MSAFP levels in the samples examined, (using a
normal approximation to the binomial test for
comparing proportions) to investigate whether the
distribution of MSAFP levels differed from the
general population.
Not all pregnancies resulting in low birth weight
infants were screened for NTD. However, distribu-
tions of gestation, weight and sex, and whether or
not the infant was light for gestational age were
similar in screened and unscreened groups. Thus
the screened group used in the following analysis
may be assumed to be a representative sample of
all low birth weight pregnancies. MSAFP was
measured by double-antibody radioimmunoassay.
3 Results
There was no significant difference between the
numbers of male and female infants. Table I shows
the distribution of MSAFP levels according to
birth weight. Overall there were 33 (8.5%) women
with raised MSAFP levels (> 2 MOM) giving fairly
strong evidence of an increased chance that
women with low birth-weight babies had raised
MSAFP values (p< 0/005). For birth-weights
under 2.0 kg there appears to be an even greater
risk: 11.7% of women had a raised MSAFP level
(p< 0.001). The same may be true for those
under 1.5 kg and under 1.0 kg but the sample size
in these two groups is insufficient for firm con-
clusions to be drawn. However, there is evidence
to suggest such an association (pooling MSAFP
into normal/raised groups, and pooling weights
< 1.5 kg, X2 test p < 0.02).
Table II shows the distribution of MSAFP accord-
ing to gestational age at delivery. There is weak
evidence of an association between MSAFP and
gestation (X2 test, pooling AFP groups above
2 MOM, ρ < 0.09). Although there may be an
increased chance of raised MSAFP levels amongst
patients delivering before 33 weeks of gestation
(p < 0.02), there is very little evidence of an asso-
ciation between raised MSAFP and prematurity as
a whole (i.e. gestation under 37 weeks). However,
for low birth weight infants born after 37 weeks of
gestation, there is strong evidence of an increased
chance of raised MSAFP levels; in this sample
9.8% of patients who were delivered after 37
weeks had raised MSAFP values (p < 0.005).
These results suggested that raised MSAFP levels
might indicate intra-uterine growth retardation
(IUGR), i.e. light for gestational age infants. To
clarify the situation, birthweights were then
compared with standard birth weight centiles [6]
according to gestation, sex and parity. An infant
was classified as light-for-dates if its birth weight
lay below the appropriate 10th centile, otherwise
it was classified as appropriate-for-dates. Sixty-four














































* expressed as multiples of the median values for normal outcome pregnancies at term.
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patients were not classifiable as they delivered
before 32 weeks of gestation, outside the range of
the available centiles.
Table III shows the results of this analysis. In the
light-for-dates group, 19 out of 203 (9.4%) had
raised MSAFP levels, whereas in the appropriate-
for-dates group, only six out of 122 (4.9%) had
raised MSAFP levels, comparable with the general
population. Thus there was strong evidence of an
increased chance of raised MSAFP in the light-
for-dates group (p < 0.005).
3.1 Spontaneous Abortions
Fifty-five pregnancies ended in spontaneous abor-
tion after 16 weeks where MSAFP levels had been
measured prior to the abortion. Of these, eight
women had raised MSAFP (14.5%). This is strong
evidence (p < 0.002) that raised MSAFP occurs
more frequently in pregnancies ending in spon-
taneous abortion than in the general population.
3.2 Stillbirths
Sixty-one pregnancies ended with a stillborn infant.
Five (8.2%) women had raised MSAFP levels and
there is little evidence to suggest that raised
MSAFP in the second trimester has any association
with subsequent stillbirth.
4 Discussion
These results are consistent with earlier studies, in
that there appears to be an increased chance of
raised MSAFP values in mothers who have infants
of low birth weight. In our sample, 8.5 % of these
patients had raised MSAFP levels at 16—21 weeks
of gestation, compared with 13 A % at 16—20
weeks reported by SMITH [5].
From the above analysis, high MSAFP in singleton
pregnancies without fetal defect would seem to be
a predictor of light-for-dates infants, and possibly
also extreme prematurity. However, the apparent
association between very premature infants, born
at 32 weeks of gestation or less, and high MSAFP,
may be due to bias: if gestation is under-estimated,
this will lead to an apparently high MSAFP level,
and an apparently early delivery.
The association between IUGR and high MSAFP is
of interest, but is unlikely to be of much practical
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use, unless the predictive ability of MS AFP could
be enhanced by combination with other tests. The
MSAFP test identifies only a small proportion of
pregnancies with IUGR (9.4%), and in addition,
less than 10% of mothers with raised MSAFP and
a normal singleton fetus, delivery a low birth-
weight infant [1, 7]; in our study 7 % of singleton
pregnancies with raised MSAFP resulted in a low
birthweight infant. Thus, increasing antenatal care
in pregnancies with raised MSAFP levels would not
likely be effective in reducing the overall incidence
of fetal growth retardation but might confer other
benefits and this association needs further study.
It seems reasonable thdt raised MSAFP levels
might be associated with spontaneous abortion
as found here since various factors which may
adversely affect the pregnancy sufficiently to
cause spontaneous abortion may be present at the
time of the test. Stillbirths are more often the
result of factors occurring later in pregnancy and
are unlikely to be detected by MSAFP testing in
the second trimester. In our sample of stillbirths,
the distribution of MSAFP levels is consistent with
that in the general pregnant population.
Summary
Maternal serum a fetoprotein (MSAFP) measurement
between 16 and 21 weeks gestation is used to define a
group of women with an increased risk of fetal abnor-
mality, particularly open neural tube defect. The test is
strongly gestation dependent and women with high
MSAFP levels require sonar scan examination to define
gestation, exclude twins and examine the fetus for obvi-
ous malformation or death. It has been reported that
women with no primary cause for raised MSAFP have an
increased incidence of low birth weight babies. Conflict-
ing reports have separately ascribed these to premature
delivery and to intra-uterine growth retardation.
We have studied the relationship between MSAFP and low
birth weight infants with respect to both prematurity and
retarded fetal growth. MSAFP values were expressed as
multiples of the appropriate weekly median (MOM) values
relating to normal pregnancies with normal outcomes at
term. For our normal population an MSAFP value of
2 MOM is the 95% centile, i.e. 5% of normal outcome
pregnancies of sure gestation will have MSAFP values in
the second trimester which are at or above 2 MOM.
Information was available on 389 women whose infants
were liveborn singletons weighing 2.5 kg or less. 33
(8.5 %) of these women had MSAFP > 2 MOM (p < 0.005)
and of the 145 women whose babies weighed less than
2kg, 17 (11.7%) had MSAFP at this level (p < 0.001)
Tab. I).
There was little evidence of an association between raised
MSAFP and premature delivery but a significant number
of women with raised MSAFP had low birthweight infants
after 37 weeks gestation (p < 0.005) (Tab. II).
When the data were analysed in relation to standard birth-
weight centiles for gestation, sex and parity, (Tab. Ill),
19 out of 203 women (9.4%) with light-for-dates babies
had raised MSAFP compared with 6 out of 122 (4.9%)
women with appropriate-for-dates babies (p < 0.005)
(Tab. III).
Raised MSAFP was also found more frequently (p<0.002)
in pregnancies ending in spontaneous abortions than in
the general population.
Thus, in the absence of fetal* abnormality, elevated
MSAFP in the second trimester may indicate a fetus at
increased risk of spontaneous abortion or intra-uterine
growth retardation.
Keywords: Birthweight, intra uterine growth retardation, maternal serum AFP, small for dates.
Zusammenfassung
Alpha-Fetoproteinspiegel im mütterlichen Serum bei
Einlingsschwangerschaften mit niedrigem Geburtsgewicht
Zur Erfassung eines erhöhten Risikos von fetalen Miß-
bildungen, speziell Neuralrohrdefekten, wird zwischen der
16. und 21. Schwangerschaftswoche das Alpha-Feto-
protein im mütterlichen Serum (MSAFP) bestimmt. Die
Konzentration korreliert eng mit dem Gestationsalter. Bei
Frauen mit erhöhtem AFP-Spiegel sollte eine Ultraschall-
untersuchung durchgeführt werden, um das Schwanger-
schaftsalter zu bestimmen und um Zwillinge sowie fetale
Mißbildungen oder einen abgestorbenen Feten auszu-
schließen. Es wurde berichtet, daß Frauen mit erhöhtem
AFP gehäuft Kinder mit niedrigem Geburtsgewicht
gebären. Ob dabei eine Frühgeburt oder eine intrauterine
Wachstumsretardierung zugrunde liegt, wird widersprüch-
lich diskutiert.
Wir untersuchten den Zusammenhang zwischen MSAFP
und niedrigem Geburtsgewicht sowohl unter dem Aspekt
der Frühgeburtlichkeit als auch der intrauterinen Wachs-
tumsretardierung. Die MSAFP-Werte wurden als Multiple
der angemessenen, wöchentlichen Mittelwerte (MOM),
die für komplikationslose Schwangerschaften mit Gebur-
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ten am Termin aufgestellt worden waren, ausgedrückt. Für
unsere Normalbevölkerung liegt ein MSAFP-Wert von
2 MOM auf der 95. Perzentile, d.h., daß bei normalem
Schwangerschaftsverlauf und sicherem Gestationsalter
5 % der Schwangeren im 2. Trimenon MS AFP-Werte bei
oder oberhalb von 2 MOM haben.
Uns lagen Werte von 389 Frauen vor, deren lebend-
geborene Kinder ein Geburtsgewicht von 2,5 kg und
weniger hatten. 33 dieser Frauen (8,5%) hatten MOM-
Werte > 2 MOM (p < 0,005). Von den 145 Frauen,
deren Kinder weniger als 2 kg wogen, hatten 17 (11,7%)
MSAFP-Werte > 2 MOM (p < 0,001, Tab. I). Es gab
wenig Hinweise für einen Zusammenhang zwischen erhöh-
tem MSAFP und einer Frühgeburt. Die Anzahl von
Frauen mit hohem AFP und Kindern mit niedrigem
Geburtsgewicht nach der 37. Schwangerschaftswoche war
dagegen signifikant erhöht (p < 0,005, Tab. II).
Nach Analyse der Daten unter Verwendung von Gewichts-
perzentilen, in denen das Gestationsalter, das Geschlecht
und die Parität berücksichtigt werden, ergab sich folgen-
des: 19 von 203 Frauen (9,4%) mit untergewichtigen
Kindern hatten ein erhöhtes MSAFP, dagegen nur 6 von
122 Frauen (4,9 %), deren Kinder normalgewichtig waren.
Dieser Unterschied ist signifikant (p < 0.005, Tab. III).
Bei Schwangerschaften, die mit einem Spontanabort ende-
ten, wurden auch öfter erhöhte MSAFP-Werte gefunden
als in normalen Schwangerschaften (p < 0,002).
Liegen keine fetalen Mißbildungen vor, kann ein angestie-
genes MSAFP im 2. Trimenon Ausdruck eines erhöhten
Risikos für einen Spontanabort oder einer intrauterinen
Wachstumsretardierung sein.
Schlüsselwörter: AFP im mütterlichen Serum, Geburtsgewicht, intrauterine Wachstumsretardierung, Small-for-date-
Babies.
Resume
Taux d'alpha-foetoprot eines seriques maternels au cours
des grossesses avec enfants de faible poids de naissance
L'estimation de 1'aFP serique maternelle (MSaFP) entre
16 et 21 semaines de gestation est utilisee pour la defini-
tion d'un groupe de femmes enceintes a risque d'avoir des
enfants porteurs de graves malformations congenitales et
particulierement de defaut de fermeture spinale. Le
dosage de 1'MSaFP a une correlation tres significative avec
Tage gestationnel et une femme enceinte presentant une
valeur elevee necessite une ochographie pour confirmer
Tage gestationnel, pour eliminer une grossesse gemellaire
et pour rechercher des malformations foetales ou les morts
intra-uterines. On a rapporte qu'il existe une augmenta-
tion significative des enfants de faible poids de naissance
chez les femmes ayant une elevation de I'MSaFP sans
cause. Des publications contradictoires ont attribue cette
augmentation aux accouchements prematures ou au
retard de croissance intra-uterin (RCIU).
Nous avons tente d'apporte un peu de lumiere sur cette
question en mesurant les concentrations de 1'MSaFP et en
les mettant en rapport avec Fincidence des accouchements
prematures et du retard de croissance intra-uterin chez les
enfants de faible poids de naissance. Les valeurs de
1'MSaFP ont ete calculees comme les multiples des
valeurs moyennes (VM), par rapport ä Tage gestationnel,
obtenues au cours des grossesses normales ayant abouti ä
un nouveau-ne unique, de poids de naissance normal, ä
terme et en bonne sante. Dans notre population normale,
une valeur de 1'MSaFP = 2 VM est au percentile 95 : 5 %
des parturientes ä terme avec des grossesses normales et
Mots-cles: oiFP serique maternelle, hypotrophie, poids de
ayant accouche d'enfants normaux ont des valeurs de
PMSaFP pendant le deuxieme trimestre > 2 VM.
Les auteurs etudient 389 meres ayant accouche d'enfants
uniques avec un poids de naissance inferieur ä 2,5 kg. La
concentration d'aFP etait > 2 VM dans le sang de 33
(8,5 %) de ces femmes enceintes entre 16 et 20 semaines
de gestation (p < 0,005) et 17 (11,7%) des 145 meres
ayant accouche d'enfants avec un poids inferieur ä 2 kg
(p < 0,001) (Tab. I).
II n'a pas ete mis en evidence de correlation significative
entre 1'MSaFP elevee et laccouchement premature, mais
un nombre significatif de femmes enceintes dont les
valeurs de 1'MSaFP etaient elevees ont accouche d'enfants
de faible poids de naissance apres 37 semaines de gesta-
tion (p < 0,005) (Tab. II).
Quand on tient compte des repartitions par rapport aux
courbes de percentiles du poids de naissance pour Tage
gestationnel, pour le sexe et pour la parite, 19 des 203
meres ayant des enfants hypotrophiques avaient des
valeurs d'MSaFP elevees (9,4%) et seulement 6 des 122
meres ayant des enfants correspondant ä Tage gestation-
nel (Tab. III).
Egalement, nous avons trouve des valeurs d'MSaFP
elevees plus frequemment (p < 0,002) au cours des gros-
sesses aboutissant ä un avortement spontan6.
Ainsi, en l'absence de malformation congenitale, 1'aFP
serique maternel (MSaFP) elevee au cours du 2eme
trimestre s'accompagne d'un risque de fausse-couche ou
de retard de croissance intra-uterin (RCIU).
naissance, retard de croissance intra-uterin.
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